We do have COVID-19 IgG/IgM Immunoassay rapid tests to fight the pandemic
0

Tu carrito está vacío

MA2034

Zika Rapid Test

This is a rapid, visual, qualitative immunochromatographic in-vitro assay for the differential detection of IgG & IgM antibodies to Zika virus in human serum, plasma, and/or whole blood samples. Sensitivity and Specificity data is available upon request. 

  • Antibody-capture immunochromatographic assay
  • Can be used with serum, plasma or whole blood samples
  • Available in cassette format

THE PROBLEM

Zika virus was first isolated in Uganda in 1947. It’s an emerging arthropod borne virus transmitted by Aedes mosquitoes. In the past, only sporadic Zika virus infections were reported. Zika can be sexually transmitted, even if the person who has Zika is asymptomatic. The virus has a large geographic distribution, including eastern and western Africa, the Indian subcontinent, Southeast Asia, and most recently, South America. The symptoms include mild fever, rash, conjunctivitis, muscle and joint pain, and headache. With the incubation period ranging between 3 to 12 days, the symptoms can often be misdiagnosed. Zika in pregnancy is known to cause serious birth effects. Because the symptoms of Zika are similar to dengue or chikungunya, testing for presence of the IgG or IgM antibodies is critical particularly for pregnant women. 

THE SOLUTION

The One Step Zika IgG/IgM Antibody Test is a rapid, cost-effective, qualitative and convenient solution  used to detect the presence of antibodies against the Zika virus. The Zika rapid test is an antibody-capture immunochromatographic assay for the simultaneous detection and differentiation of IgM & IgG antibodies to Zika virus in human serum, plasma and/or whole blood samples. This assay only provides a preliminary result. Clinical expertise and professional judgment should be sought to further evaluate the result of the test. Sensitivity and specificity data is available upon request. 

To test, a sample of whole blood, serum or plasma is added to the sample well of the test device. The test works by detecting IgG and IgM antibodies to Zika in the sample as it flows through the assay by first, Zika virus-specific antigens conjugated with colloidal gold that attach to IgG and IgM antibodies to Zika and provide a “visual tag” for the antigen-antibody-colloidal gold complex and second, by two separate test lines - one with immobilized anti-human IgM antibodies and one with immobilized anti-human IgG antibodies - that capture the relevant antigen-antibody-colloidal gold complex. When a test line becomes concentrated with antibodies, the concentrated visual tag produces a visible pink-colored band that is confirmation of the presence of the target molecule (Zika IgM or IgG antibodies). The presence of a colored band/pink line for either or both IgM and IgG antibodies to Zika indicates a positive result for Zika infection.

This is a rapid, visual, qualitative immunochromatographic in-vitro assay for the differential detection of IgG & IgM antibodies to Zika virus in human serum, plasma, and/or whole blood samples. Sensitivity and Specificity data is available upon request. 

  • Antibody-capture immunochromatographic assay
  • Can be used with serum, plasma or whole blood samples
  • Available in cassette format

THE PROBLEM

Zika virus was first isolated in Uganda in 1947. It’s an emerging arthropod borne virus transmitted by Aedes mosquitoes. In the past, only sporadic Zika virus infections were reported. Zika can be sexually transmitted, even if the person who has Zika is asymptomatic. The virus has a large geographic distribution, including eastern and western Africa, the Indian subcontinent, Southeast Asia, and most recently, South America. The symptoms include mild fever, rash, conjunctivitis, muscle and joint pain, and headache. With the incubation period ranging between 3 to 12 days, the symptoms can often be misdiagnosed. Zika in pregnancy is known to cause serious birth effects. Because the symptoms of Zika are similar to dengue or chikungunya, testing for presence of the IgG or IgM antibodies is critical particularly for pregnant women. 

THE SOLUTION

The One Step Zika IgG/IgM Antibody Test is a rapid, cost-effective, qualitative and convenient solution  used to detect the presence of antibodies against the Zika virus. The Zika rapid test is an antibody-capture immunochromatographic assay for the simultaneous detection and differentiation of IgM & IgG antibodies to Zika virus in human serum, plasma and/or whole blood samples. This assay only provides a preliminary result. Clinical expertise and professional judgment should be sought to further evaluate the result of the test. Sensitivity and specificity data is available upon request. 

To test, a sample of whole blood, serum or plasma is added to the sample well of the test device. The test works by detecting IgG and IgM antibodies to Zika in the sample as it flows through the assay by first, Zika virus-specific antigens conjugated with colloidal gold that attach to IgG and IgM antibodies to Zika and provide a “visual tag” for the antigen-antibody-colloidal gold complex and second, by two separate test lines - one with immobilized anti-human IgM antibodies and one with immobilized anti-human IgG antibodies - that capture the relevant antigen-antibody-colloidal gold complex. When a test line becomes concentrated with antibodies, the concentrated visual tag produces a visible pink-colored band that is confirmation of the presence of the target molecule (Zika IgM or IgG antibodies). The presence of a colored band/pink line for either or both IgM and IgG antibodies to Zika indicates a positive result for Zika infection.

Noticias y actualizaciones

Regístrate gratis para obtener lo último en ventas, nuevos lanzamientos y más…

maternal and newborn health news